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Background: Hereditary angioedema (HAE) due to C1 inhibitor deficiency is a rare but serious and potentially
life-threatening disease marked by spontaneous, recurrent attacks of swelling. The study objective was to
characterize direct and indirect resource utilization associated with HAE from the patient perspective in Europe.
Methods: The study was conducted in Spain, Germany, and Denmark to assess the real-world experience of HAE
via a cross-sectional survey of HAE patients, including direct and indirect resource utilization during and between
attacks for patients and their caregivers over the past 6 months. A regression model examined predictors of
medical resource utilization.
Results: Overall, 164 patients had an attack in the past 6 months and were included in the analysis. The most
significant predictor of medical resource utilization was the severity of the last attack (OR 2.6; p < 0.001). Among
patients who sought medical care during the last attack (23%), more than half utilized the emergency department. The
last attack prevented patients from their normal activities an average of 4–12 hours. Patient and caregiver absenteeism
increased with attack severity and frequency. Among patients who were working or in school (n = 120), 72 provided
work/school absenteeism data, resulting in an estimated 20 days missing from work/school on average per year;
51% (n = 84) indicated that HAE has hindered their career/educational advancement.
Conclusion: HAE poses a considerable burden on patients and their families in terms of direct medical costs and
indirect costs related to lost productivity. This burden is substantial at the time of attacks and in between attacks.
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Hereditary angioedema (HAE) is an autosomal domin-
ant disorder caused by a deficiency of C1 inhibitor. It is
a rare but serious and potentially life-threatening dis-
ease marked by spontaneous, recurrent attacks of swell-
ing, typically in the gastrointestinal tract, extremities,
face, larynx, and/or urogenitals [1-6]. The prevalence
has been estimated to be around 1 in 50,000 [6,7]. At-
tacks vary unpredictably with respect to severity, fre-
quency, and body site, and can be life-threatening due* Correspondence: Aygoeren@em.uni-frankfurt.de
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article, unless otherwise stated.to risk of asphyxiation [4,8,9]. Symptoms often begin in
early childhood and persist throughout patients’ lives,
and an accurate diagnosis may be delayed for 10 years
or more [2,5,6].
While there is no cure for HAE, existing treatment op-
tions have substantially reduced mortality [10]. Treatment
strategies include treatment of acute attacks, pre-procedure
attack prophylaxis, and long-term prophylaxis to minimize
the frequency and severity of attacks [11-16]. The available
treatment options at the time of the study varied between
countries and mostly consisted of a plasma derived C1 in-
hibitor concentrate and a B2 bradykinin receptor antagon-
ist for the treatment of acute attacks [14-16]. Long-term
prophylaxis options have traditionally involved attenu-
ated androgens and anti-fibrinolytic agents, althoughCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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countries [14-17]. Recently, two additional treatment op-
tions became available in Europe: a recombinant C1 in-
hibitor for the treatment of acute attacks [18] and a
nanofiltered C1 inhibitor [human] for the treatment, pre-
procedure prevention, and long-term prevention of angio-
edema attacks in adults and adolescents with HAE [19].
Given the unpredictable nature of HAE and the severity
of attacks, use of emergency medical care may be high.
Based on a nationwide database in the US, there were
5040 emergency department visits for HAE in 2006–2007,
41% of which resulted in hospitalization [20]. Moreover,
the findings from a survey of individuals with HAE in the
US showed that HAE may have a substantial impact on
work productivity and medical resource utilization [21].
However, such data on the socioeconomic consequences
of HAE are lacking in Europe. Also, the use of caregivers
for HAE has not been explored previously. Thus, the ob-
jective of this study was to characterize direct and indirect
resource utilization associated with HAE from the patient
perspective in Europe, focusing on Spain, Germany, and
Denmark.
Methods
The Hereditary Angioedema Burden of Illness Study in
Europe (HAE-BOIS-Europe) was a cross-sectional study
aimed at assessing the real-world patient experience of
HAE in Spain, Germany, and Denmark. Patients at least
12 years of age who were diagnosed with HAE type I or
type II were recruited from patient organizations and
from clinical practice centers of excellence. In Spain, all
members of the patient organization and a random sam-
ple of patients in the Spanish Registry Database (which
includes patients from across the country) were invited;
in Germany, all members of the patient organization and
a random sample of patients from the clinical center
database were invited; and in Denmark, all known pa-
tients with HAE in the country were invited between the
clinical center and the patient organization.
Patients completed a web- or paper-based survey, de-
pending on their preference. Data collection took place in
May-December 2011. The study was reviewed and ap-
proved by institutional review boards per local require-
ments. Participants provided online informed consent (or
written informed consent if completing the paper version
of the survey) prior to taking the survey. For participants
under the age of 18, parental consent was obtained in
addition to the adolescent’s assent. The survey was devel-
oped based on consultation with HAE clinical experts and
pilot-tested with patients in each country. Items on clinical
characteristics, humanistic burden, and resource utilization
were collected retrospectively. Patients were asked about
their most recent attack, as well as about the impact of
HAE between attacks over the last 6 months. The studywas not designed to examine specific treatment outcomes;
however, patients were asked to identify their current and
previous HAE medications. The full methodology and hu-
manistic burden data from this study are described else-
where [22,23].
This manuscript reports the results related to direct
medical resource utilization (medication use for acute at-
tacks and prophylaxis, acute or emergency medical care
for the last attack, routine care visits, and use of antianxi-
ety or antidepressant medication) and indirect resource
utilization (lost productivity and absenteeism from work/
school and time lost from usual activities during attacks
and between attacks for the patient and their caregivers).
The impact of HAE on work/school productivity both
during the recent attack and in between attacks over the
past six months was measured on an 11-point numeric
rating scale, consistent with other patient-reported mea-
sures of productivity [24]. The survey items and scoring
are reported in Table 1. An annual rate of work/school ab-
senteeism for HAE patients was estimated from the re-
ported amount of time missed from work/school for the
last attack, frequency of attacks, and the reported amount
of time missed from work/school between attacks over the
past six months (among patients with non-missing data).
Caregivers were defined as “a volunteer (unpaid) helper
because of HAE (e.g., to aid in your ability to attend your
medical appointments or to assist you in your daily activ-
ities)”. The use of caregivers (including the amount of time
they missed from work/school/leisure while assisting the
HAE patient), both during the last attack and between at-
tacks, was also collected.
Analyses were descriptive, reporting means and fre-
quencies, and differences among subgroups were ex-
plored using t-tests and chi-square tests for continuous
and categorical variables, respectively. Two logistic re-
gression models were developed to evaluate associations
between potential explanatory variables and 1) having a
treatment visit for the last attack, and 2) “six-month
medical resource utilization”, as described in Table 1.
Potential explanatory variables included the severity of
the last attack, duration of swelling of the last attack, at-
tack frequency, country, age, gender, household income,
having medication at home for self-administration dur-
ing attacks, and use of medication for long-term prophy-
laxis (by type). The substantial differences in treatment
patterns and healthcare system configurations in the
three countries allowed for only minimal comparisons
across countries.
Results
Of the 186 HAE-BOIS-Europe participants, 164 (88%)
experienced an attack in the past six months and formed
the analysis sample, including 58 (35%) from Spain, 62
(38%) from Germany, and 44 (27%) from Denmark.
Table 1 Survey items on direct and indirect resource utilization
Concept Item Scoring
Direct medical resource
utilization over the past
6 months
“Treatment visit for
last attack”
Please report the type of visit you had, to the best of your
knowledge, for your most recent attack.
Endorsement of 0 or 1 item = low
Endorsement of at least one type of treatment visit = 1
“Used medication for
last attack”
Which prescription medication(s) were used for the
treatment of your most recent attack? Please indicate the
name/type of all medication prescribed by your doctor(s)
you used for the most recent HAE attack.
Endorsement of 2 =medium
Endorsement of at least one type of medication = 1 Endorsement of 3 or 4 = high
“Had a routine care
visit for HAE in the
past 6 months”
In the past 6 months, how many times have you been to the
hospital or clinic for routine care related to HAE? Please
exclude visits related to HAE attacks.
Endorsement of at least one visit = 1
“Used anti-anxiety or
anti-depressant
medication”
Which of the following medications have you taken during
the past 6 months (check all that apply)?
Endorsement of “anti-anxiety medication” and/or “anti-
depressants” = 1
Estimated absenteeism
over one year
“Attacks per year” HAE attacks may be mild, moderate, or severe. In the past
year, approximately how often did you experience an HAE
attack of any severity (please account for all attacks
regardless of severity)?
1. Reported attack frequency
extrapolated to estimate annual
frequency.
• Less than once a month (Approximately how many per
year?___)
2. Annual frequency multiplied by
amount of absenteeism for the last
attack.
• At least once a month but less than once a week
(Approximately how many per month?___)
3. Added to twice the amount of
absenteeism between attacks over
the past 6 months.
• At least once a week (Approximately how many per
week?___)
“Absenteeism during
the last attack”
During your most recent attack, how many hours or days did
you miss from work and/or school because of problems
associated with the HAE attack? Include hours you missed
on sick days, times you arrived late, left early, etc., because of
the HAE attack.
“Absenteeism
between attacks over
the past 6 months”
In the past six months, how many days did you miss from
work and/or school because of problems associated with
HAE in between attacks? Include hours you missed on sick
days, times you arrived late, left early, etc., in between
attacks.
Attack severity “Attack pain severity” What was the worst pain you had during your most recent
HAE attack? 0 = No pain; 1 = Mild; 2 = Moderate; 3 = Severe
Average of pain and swelling scores
“Attack swelling
severity”
How would you describe the severity of swelling of your
most recent attack?
• 1 = Mild (noticeable symptoms but they did not affect your
daily activities)
• 2 = Moderate (you wanted intervention for symptoms during
the attack or your daily activities were affected)
• 3 = Severe (treatment or intervention was required or you were
unable to perform daily activities)
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The average age was 43 years and 100 (61%) were female.
Patients were diagnosed with HAE an average of 12 years
after symptom onset. Thirty-eight patients (23%) reported
having HAE attacks at least once a week, 67 (41%) re-
ported having attacks at least once a month but less than
once a week, and 59 (36%) reported having attacks lessthan once a month. The average number of attacks per
year (estimated) was 15, 52, and 29 in Spain, Germany,
and Denmark, respectively. Fifty-four patients (33%) re-
ported experiencing no pain or mild pain during the last
HAE attack, 74 (45%) reported experiencing moderate
pain, and 36 (22%) reported experiencing severe pain; this
did not vary significantly by country.
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Treatment of the acute attack
Nearly all patients (n = 150; 91%) had medication at
home to treat acute attacks. A total of 109 patients
(66%) reported that they treated the attack with an HAE
acute-specific medication, either plasma-derived C1 in-
hibitor and/or B2 bradykinin receptor antagonist. Even
though the countries did not differ significantly with re-
spect to the severity of the last attack, the use of HAE
acute-specific medication for the last attack varied
among the three countries [90% (n = 56) in Germany,
61% (n = 27) in Denmark, and 45% (n = 26) in Spain;
p < 0.001]. This also varied by attack frequency; 100%
(n = 38) of patients who experienced attacks at least once
a week used an appropriate acute medication, compared
with 70% (n = 47) of patients with attacks at least once a
month but less than once a week, and 41% (n = 24) of
patients with attacks less than once a month (p < 0.001).
Among patients who experienced severe pain during their
last attack, 83% (n = 30) used an appropriate acute medica-
tion, compared to 72% (n = 53) of patients with moderate
pain, and 48% (n = 26) of patients with mild pain (p = 0.001).
Overall, 22% (n = 36) of patients did not take any medication
for the last attack.
A total of 37 patients (23%) sought medical care from at
least one source during the last attack, with the emergency
department being the most often visited (n = 20; 54%); 5 of
the patients (14%) were hospitalized at least overnight
(Figure 1). Use of emergency departments for the last at-
tack increased with increasing pain severity of the last
attack [19% (n = 7) of patients with severe pain used an
emergency department compared to 16% (n = 12) of pa-
tients with moderate pain and 2% (n = 1) of patients with54%
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Figure 1 Types of treatment visits for most recent HAE attack (N = 37
visit for the attackmild or no pain; (p = 0.016)]. The severity of the last attack
(as measured by pain and swelling) was also a strong
predictor in the regression models of treatment visits
for the last attack and of six-month medical resource
utilization. Specifically, as attack severity increased by 1
point on a scale from 0 (least severe) to 3 (most severe),
patients were 3.0 times more likely to have a treatment
visit (p < 0.001) and 2.6 times more likely to have higher
six-month medical resource utilization (p < 0.001). Also,
for each increase in swelling duration of approximately
12 hours, patients were 1.5 times more likely to have a
treatment visit (p = 0.008).
Treatment in between attacks
Over the past six months, 98 patients (60%) reported seeing
a healthcare provider for HAE in between attacks. Use of
long-term prophylaxis with either attenuated androgens or
tranexamic acid was reported by 56 patients (34%), the
majority of whom (n = 40; 71%) were taking attenuated
androgens. Overall, 61 patients (37%) reported discontinu-
ing one or more long-term prophylaxis medications in the
past, primarily due to side effects or lack of efficacy. Among
these, 38 (62%) discontinued attenuated androgens,
18 (30%) discontinued tranexamic acid, and 5 (8%) discon-
tinued both tranexamic acid and attenuated androgens. In
addition, 17 patients (10%) had used an anti-anxiety or
antidepressant medication in the past six months.
Indirect resource utilization
Impact of the acute attack on productivity for patients and
their caregivers
Of the 164 patients, 120 (73%) reported that they were
either working or going to school (73 working full-time;8% 8%
5% 5%
patients). Note: Four patients had more than one type of treatment
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in school), and 72 (60%) provided work/school absentee-
ism data, which was optional in the survey. Of these 72
patients, 40 (56%) reported missing time from work/
school during the last attack. Higher pain severity of
the last attack was associated with a greater impact on
work/school productivity (r = 0.39; p = 0.001). On a scale
from 0–10 (higher worse), the last attack impaired pa-
tients’ work/school productivity a mean of 4.4. The last
attack prevented patients from their normal activities an
average of 4–12 hours and this did not vary significantly
by body site (Figure 2).
Figure 3 shows that work/school absenteeism for pa-
tients and caregivers during the last attack increased as
pain severity increased. Overall, 86 patients (52%) reported
that they had assistance from a caregiver during the last
attack (primarily a family member), including 69% (n = 25)
of patients with severe pain, 64% (n = 47) of patients with
moderate pain, and 26% (n = 14) of patients with no pain
or mild pain (p < 0.001). Patients with severe pain also re-
ported that their caregivers missed more time during the
last attack than patients with no pain/mild pain or moder-
ate pain (2.1 vs. 1.2 and 1 day, respectively; p = 0.015).
Impact of HAE on productivity in between attacks for
patients and caregivers
In addition, absenteeism between attacks over the past six
months for both patients and caregivers increased as at-
tack frequency increased. Specifically, the average numbers<2h        2-4h     4-1
Figure 2 Duration prevented from daily activities by attack sitea. aFor
from performing your normal activities? Median duration for less common
to 2-4 h (n = 6); respiratory/laryngeal = 4-12 h (n = 3). Differences across siteof missed days for patients were 2.2, 6.0, and 11.6 among
patients with attacks less than once a month, at least once
a month but less than once a week, and at least once a
week, respectively (p = 0.128), and they reported that their
caregivers missed 3.3, 3.6, and 10.1 days, respectively
(p = 0.088). Patients also experienced decreased productivity
due to HAE between attacks, with a mean of 1.9 on
a 0–10 scale.Total estimated absenteeism over 12 months
Based on estimated attack frequency and reported absen-
teeism data, overall, patients are estimated to miss appro-
ximately 20 days of work/school per year due to HAE.
Patients who reported severe pain during the recent attack
had a higher absenteeism estimate of approximately 28 days
per year (Table 2).Long-term consequences for education and careers
High proportions of patients reported that HAE has hin-
dered their career and/or educational advancement, pre-
vented them from applying to certain jobs, caused them
to leave a position permanently, or caused them to
switch positions within a company (Figure 4). This was
significantly related to attack frequency; 57% (n = 60) of
patients with attacks at least once a month reported that
HAE has hindered their career and/or educational ad-
vancement compared to 41% (n = 24) of patients with at-
tacks less than once a month (p = 0.043).2h 12-24h   1-2d       3d         4d      >4d 
approximately how long did your most recent HAE attack stop you
sites: “other” (including joints and low back) = <2 h (n = 7); face = <2
s not statistically significant (p = 0.560).
29% 26%
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Figure 3 Work/school absenteeism during last attack by pain severity. Percentage who missed time and reported mean days missed.
ap-values for difference in percentage who missed time. Percentages based on 72 patients who were employed or in school and provided
absenteeism data. Percent of caregivers based on full sample (N = 164). Note: Means based on number of patients (n = 40) and caregivers (n = 86)
who missed time. Caregiver time includes leisure time. Data missing for missed time for 31 caregivers.
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This study describes the socioeconomic burden of HAE in
Europe, related to the treatment of acute attacks and routine
care, work/school absenteeism and productivity impairment
during and in between attacks, and long-term consequences
for career and educational achievement. The findings sug-
gest that HAE may lead to substantial direct and indirect
costs, corroborating results observed in the US [21].Table 2 Reported and estimated work/school absenteeism du
Pain severity of
the last attack
Estimated attacks per year Reported time missed
last attack (days)
Mean ± SD / median (range)
(95% CI)
Mean ± SD / median (ra
(95% CI)
Overall (n = 67) 33.2 ± 39.6 1.0 ± 1.6
12.0 (1.0-156.0) 0.25 (0.0-8.0)
(23.7-42.7) (0.6-1.4)
None/mild (n = 20) 43.7 ± 48.7 0.5 ± 0.9
24.0 (1.0-156.0) 0.0 (0.0-3.0)
(32.8-54.6) (0.3-0.7)
Moderate (n = 33) 30.4 ± 37.3 1.0 ± 1.6
12.0 (1.0-156.0) 0.4 (0.0-8.0)
(6.3-17.7) (0.75-1.2)
Severe (n = 14) 24.8 ± 28.1 1.8 ± 1.9
12.0 (5.0-104.0) 1.1 (0.0-7.0)
(17.3-32.3) (1.3-2.3)
Note: Estimates based on patients who provided absenteeism data (n = 72); 5 outlie
absenteeism ≥ 258 days); thus, final sample size = 67.
aEstimated absenteeism over 12 months calculated as the mean of the estimates co
these estimates differ from those based on the mean time missed as a group.
Confidence Intervals of means reported.Attack pain severity was an important predictor of
direct and indirect resource utilization. Greater pain sever-
ity was associated with an increased likelihood of using
the emergency department for treatment of the attack,
treating the attack with an acute medication, decreased
productivity during the attack, greater absenteeism for pa-
tients and their caregivers during the attack, and greater
six-month medical resource utilization. Similar to oure to HAE
for Reported time missed between
attacks in past 6 months (days)
Estimated total absenteeism
over 12 monthsa (days)
nge) Mean ± SD / median (range)
(95% CI)
Mean ± SD / median (range)
(95% CI)
1.9 ± 2.5 19.9 ± 35.0
1.0 (0.0-11.0) 8.0 (0.0-210.0)
(1.3-2.5) (11.5-28.2)
2.1 ± 2.7 19.3 ± 47.0
1.1 (0.0-11.0) 5.0 (0.0-210.0)
(0.5-1.7) (8.8-29.8)
1.2 ± 1.6 16.8 ± 29.2
0.5 (0.0-6.0) 6.3 (0.0-140.0)
(1.0-1.4) (11.8-20.8)
3.3 ± 3.4 28.2 ± 28.2
3.0 (0.0-10.0) 17.3 (0.0-104.0)
(2.4-4.2) (20.7-35.7)
rs identified and removed (estimated attacks per year ≥ 208 or estimated
mputed at the individual-level; given that the absenteeism data are skewed,
9%
10%
36%
40%
42%
0% 5% 10% 15% 20% 25% 30% 35% 40% 45%
Switched positions within a company
Left a position permanently
Prevented from career advancement
Prevented from applying to certain jobs
Hindered educational advancement
Percent of patients 
Figure 4 Impact of HAE on career and education. Note: 84 patients (51%) reported that HAE hindered their educational and/or career
advancement.
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senteeism correlates with increasing patient reported at-
tack severity [25].
Time lost from usual activities did not vary significantly
by body site affected, suggesting that attacks in all body
sites have a limiting effect. Attack frequency was also as-
sociated with socioeconomic burden. Over the past six
months, higher attack frequency was associated with de-
creased productivity and higher absenteeism. Higher attack
frequency was also associated with difficulty advancing in
one’s education or career. Such long-term productivity
losses represent a substantial opportunity cost for the indi-
vidual and their family related to not achieving their full
potential in their education and careers.
As with any study of this nature, while systematic re-
cruitment was attempted, participation was ultimately
based on self-selection, which may affect the representa-
tiveness of the study population. Although the estimated
total number of HAE patients differs largely between the
countries involved, equal numbers were attempted to re-
cruit in each country, so as to receive the target sample
size of 150 patients, which is consistent with other bur-
den of illness studies in rare diseases [26,27] Attempts
were made to ensure generalizable country specific sam-
pling by ways of systematic or random selection. Yet, it
cannot be excluded that the willingness of a patient to
participate in a survey, increases with disease severity.
We also performed an analysis of a potential selection
bias by route of recruitment, either via patient organization
or clinical center. Such analysis demonstrated no signifi-
cant difference in the proportion of patients recruited via
each route of recruitment. Also, the clinical characteristics
of the recent attack (pain severity, swelling severity, time totreatment in each country, as well as duration of swelling
in German and Spanish participants) showed no signifi-
cant differences. Outcome measures for direct resource
utilization (percentage of patients with medication to treat
attack at home, percentage of treated attacks, visits for
treatment of recent attack, medication used to treat
anxiety or depression) were also not significantly differ-
ent between patients by recruitment route and country.
Likewise, indirect resource utilization as measured by
impact items (impact on work and school productivity
as well as impact on daily activites, each with recent at-
tack or between attacks) and report on being prevented
from career or educational advancement were not signifi-
cantly different between patients by recruitment route and
country. Despite different routes of recruitment, the data
obtained seem to be consistent.
The survey relied on self-reported, retrospective data,
which carries the potential for recall bias, although HAE
patients often keep symptom diaries. Data collected reflect
the treatment options available at the time of the study (in
2011), which varied between countries. As this study was
observational with small numbers representing different
treatments, treatment-specific subgroup analyses were not
feasible. For the most part, country comparisons were not
feasible given different treatment availability, cultural atti-
tudes toward health service use, and health care system
configuration; all country comparisons made, including
those regarding attack frequency and medication use, may
reflect such differences. In estimating absenteeism over a
one year period, it was assumed that the severity of the last
attack and absenteeism during the last attack were repre-
sentative of the average attack for the patient, although
the severity of attacks is known to be unpredictable. In
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(n = 72) of patients either working or attending school
[56% (n = 40) of whom reported absenteeism], although
attack severity and frequency did not differ for these pa-
tients compared to patients for whom such data was un-
available. Also, this study did not assess lost leisure time
for patients and therefore may underestimate patient-level
burden. Nevertheless, our findings, particularly those re-
lated to absenteeism and long-term career/educational im-
pact, are highly comparable to those observed in the US
HAE burden of illness and Sweha-Reg studies [21,25,28].
Moreover, this study adds to the literature in the assess-
ment of patient-reported use of caregivers due to HAE,
which contributes to patient-level and societal burden.Conclusion
As HAE is a rare disease, economic burden at the popula-
tion level may be relatively small; however, our findings
highlight the substantial socioeconomic burden HAE poses
to patients and their families. Our data show that patients
with frequent and severe attacks experience greater inter-
ference in their education and careers, as well as increased
use of emergency departments and acute medication. As
such, further exploration is warranted with respect to the
potential benefits of different treatment strategies.Abbreviations
HAE: Hereditary angioedema; HAE-BOIS-Europe: Hereditary Angioedema
Burden of Illness Study in Europe.Competing interests
The study was funded by ViroPharma SPRL-BVBA.
1EAP has received sponsorship for educational purposes and has provided
consultancy services or has participated in clinical trials sponsored by
CSL-Behring, Jerini AG/Shire, Sobi, and ViroPharma.
2AB has been involved in clinical research or educational events involving
CSL Behring, Jerini AG/Shire, Sobi and ViroPharma.
3 KB and EH worked for Oxford Outcomes Inc., an ICON plc company, at the
time this study was undertaken. Oxford Outcomes Inc. consults for
ViroPharma.
4ZS is an employee of ViroPharma.
5SW receives consulting fees from ViroPharma.
6HBB is the Executive Director of HAEi – International Patient Organization
for C1 Inhibitor Deficiencies, which receives funding from most
pharmaceutical companies, including ViroPharma.
7TC received sponsorship for educational purposes, has been paid for
providing consultancy services, or has taken part in clinical trials sponsored
by Jerini AG/Shire, CSL-Behring, Pharming NV, Sobi, and ViroPharma.Authors’ contributions
EAP, AB and TC contributed to the study design, participated in the
acquisition and analysis of patient data and provided substantive input to
the manuscript. KB and EH contributed to the study design, provided input
on survey design, analysis, and medical writing support on behalf of the
BOIS-EU Steering Committee. ZS coordinated the work of the Steering
Committee, performed literature searches, and provided substantive input to
the manuscript. SW contributed to the study design and drafted the
manuscript. HBB contributed to the study design, participated in the
acquisition of patient data and provided substantive input to the manuscript.
All authors read and approved the final manuscript.Acknowledgements
The authors wish to acknowledge and thank the following organizations for
their assistance with HAE patient recruitment for this study: Hudafdeling I og
Allergicentret, Odense Universitetshospital, Denmark; Klinik für Kinder – und
Jugendmedizin, Universitätsklinikum Frankfurt, Goethe-Universität Frankfurt,
Germany; Servicio de Alergia, Hospital Universitario La Paz, Spain; HAEi -
International Patient Organization for C1 Inhibitor Deficiencies; the Danish HAE
Patient Association (patientforeningen HAE danmark); the German HAE Patient
Association (HAE Vereinigung e.V.); and the Spanish Association for Hereditary
Angioedema (AEDAF).
Author details
1Department for Children and Adolescents, Angioedema Centre, University
Hospital Frankfurt, Goethe University, Theodor-Stern-Kai 7, 60596 Frankfurt,
Germany. 2HAE Centre Denmark, Department of Dermatology and Allergy
Centre, Odense University Hospital, 5000 Odense C, Denmark. 3Oxford
Outcomes Inc., an ICON plc company, 7315 Wisconsin Ave, Suite 250 W,
20814 Bethesda, MD, USA. 4ViroPharma, Chatsworth House, 29 Broadway, SL6
1LY Maidenhead, UK. 5SHW Health Ltd, 40 Lena Gardens, W6 7PZ London,
UK. 6HAEi – International Patient Organization for C1 Inhibitor Deficiencies,
Soenderholmvej 158, DK-8361 Bering, Hasselager, Denmark. 7Allergy
Department, Hospital La Paz Institute for Health Research (IdiPaz), Biomedical
Research Network on Rare Diseases U754 (CIBERER), University Hospital La
Paz, Paseo de la Castellana 261, 28046 Madrid, Spain.
Received: 24 January 2014 Accepted: 16 June 2014
Published: 4 July 2014References
1. Agostoni A, Cicardi M: Hereditary and acquired C1-inhibitor deficiency:
biological and clinical characteristics in 235 patients. Medicine 1992,
71:206–215.
2. Frank MM, Gelfand JA, Atkinson JP: Hereditary angioedema: the clinical
syndrome and its management. Ann Intern Med 1976, 84:580–593.
3. Caballero T, Baeza M, Cabanas R, Campos A, Cimbollek S, Gomez-Traseira C,
Gonzalez-Quevedo T, Guilarte M, Jurado-Palomo J, Larco JI, Lopez-Serrano MC,
Lopez-Trascasa M, Marcos C, Munoz-Caro JM, Pedrosa M, Prior N, Rubio M,
Sala-Cunill A: Consensus statement on the diagnosis, management, and
treatment of angioedema mediated by bradykinin: part I: classification,
epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis.
J Investig Allergol Clin Immunol 2011, 21:333–347.
4. Bork K, Meng G, Staubach P, Hardt J: Hereditary angioedema: new
findings concerning symptoms, affected organs, and course. Am J Med
2006, 119:267–274.
5. Bygum A: Hereditary angio-oedema in Denmark: a nationwide survey.
Br J Dermatol 2009, 161:1153–1158.
6. Zuraw BL: Clinical practice: hereditary angioedema: [Review] [53 refs].
N Engl J Med 2008, 359:1027–1036.
7. Cicardi M, Agostoni A: Hereditary angioedema. N Engl J Med 1996,
334:1666–1667.
8. Bork K, Hardt J, Schicketanz KH, Ressel N: Clinical studies of sudden upper
airway obstruction in patients with hereditary angioedema due to C1
esterase inhibitor deficiency. Arch Intern Med 2003, 163:1229–1235.
9. Bork K, Hardt J, Witzke G: Fatal laryngeal attacks and mortality in
hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol
2012, 130:692–697.
10. Cicardi M, Zanichelli A: Angioedema due to C1 inhibitor deficiency in
2010. Intern Emerg Med 2010, 5:481–486.
11. Caballero T, Farkas H, Bouillet L, Bowen T, Gompel A, Fagerberg C,
Bjokander J, Bork K, Bygum A, Cicardi M, De CC, Frank M, Gooi JHC,
Longhurst H, Martinez-Saguer I, Nielsen EW, Obtulowitz K, Perricone R, Prior
N: International consensus and practical guidelines on the gynecologic
and obstetric management of female patients with hereditary
angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol
2012, 129:308–320.
12. Cicardi M, Bork K, Caballero T, Craig T, Li HH, Longhurst H, Reshef A, Zuraw B,
HAWK (Hereditary Angioedema International Working Group): Evidence-based
recommendations for the therapeutic management of angioedema owing
to hereditary C1 inhibitor deficiency: consensus report of an International
Working Group. Allergy 2012, 67:147–157.
Aygören-Pürsün et al. Orphanet Journal of Rare Diseases 2014, 9:99 Page 9 of 9
http://www.ojrd.com/content/9/1/9913. Gower RG, Busse PJ, Aygören-Pürsün E, Barakat AJ, Caballero T, Davis-Lorton
M, Farkas H, Hurewitz DS, Jacobs JS, Johnston DT, Lumry W, Maurer M:
Hereditary angioedema caused by C1-esterase inhibitor deficiency: a
literature-based analysis and clinical commentary on prophylaxis
treatment strategies. World Allergy Organ J 2011, 4:S9–S21.
14. Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ, Zuraw B, Aygören-
Pürsün E, Craig T, Binkley K, Hebert J, Ritchie B, Bouillet L, Betschel S, Cogar
D, Dean J, Devaraj R, Hamed A, Kamra P, Keith PK, Lacuesta G, Leith E, Lyons
H, Mace S, Mako B, Neurath D, Poon MC, Rivard GE, Schellenberg R, Rowan
D, Rowe A, et al: 2010 International consensus algorithm for the
diagnosis, therapy and management of hereditary angioedema.
Allergy Asthma Clin Immunol 2010, 6:24.
15. Caballero T, Baeza ML, Cabanas R, Campos A, Cimbollek S, Gomez-Traseira C,
Gonzalez-Quevedo T, Guilarte M, Jurado-Palomo J, Larco JI, Lopez-Serrano MC,
Lopez-Trascasa M, Marcos C, Munoz-Caro JM, Pedrosa M, Prior N, Rubio M,
Sala-Cunill A, Spanish Study Group on Bradykinin-Induced Angioedema (SGBA):
Consensus statement on the diagnosis, management, and treatment of
angioedema mediated by bradykinin: part II: treatment, follow-up, and
special situations. [Review][Erratum appears in J Investig Allergol Clin
Immunol. 2012;22(2):3 p following 153]. J Investig Allergol Clin Immunol 2011,
442(21):422–441.
16. Aygören-Pürsün E, Martinez-Saguer I, Rusicke E, Klingebiel T, Kreuz W: On
demand treatment and home therapy of hereditary angioedema in
Germany - the Frankfurt experience. Allergy Asthma Clin Immunol 2010,
6:21.
17. Maurer M, Magerl M: Hereditary angioedema: an update on available
therapeutic options: [Review]. J Dtsch Dermatol Ges 2010, 8:663–672.
18. European Medicines Agency: Ruconest: summary of product
characteristics. 2010. http://www.ema.europa.eu/docs/en_GB/
document_library/EPAR_-_Product_Information/human/001223/
WC500098542.pdf.
19. European Medicines Agency: Cinryze: summary of product characteristics. 2011.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_
Information/human/001207/WC500108895.pdf.
20. Zilberberg MD, Nathanson BH, Jacobsen T, Tillotson G: Descriptive
epidemiology of hereditary angioedema emergency department visits in
the United States, 2006–2007. Allergy Asthma Proc 2011, 32:390–394.
21. Wilson DA, Bork K, Shea EP, Rentz AM, Blaustein MB, Pullman WE: Economic
costs associated with acute attacks and long-term management of
hereditary angioedema. Ann Allergy Asthma Immunol 2010, 104:314–320.
22. Bygum A, Aygören-Pürsün E, Caballero T, Beusterien K, Gholizadeh S,
Musingarimi P, Wait S, Boysen H: The hereditary angioedema burden of
illness study in Europe (HAE-BOIS-Europe): background and
methodology. BMC Dermatol 2012, 12:4.
23. Caballero T, Aygören-Pürsün E, Bygum A, Beusterien K, Hautamaki E, Sisic Z,
Wait S, Boysen H: The humanistic burden of hereditary angioedema:
results from the burden of illness study in Europe. Allergy Asthma Proc
2014, 35(1):47–53.
24. Despiegel N, Danchenko N, Francois C, Lensberg B, Drummond MF: The
use and performance of productivity scales to evaluate presenteeism in
mood disorders. [Review]. Value Health 2012, 15:1148–1161.
25. Nordenfelt P, Dawson S, Wahlgren C-F, Lindfors A, Mallbris L, Björkander J:
Quantifying the burden of disease and perceived health state in patients
with hereditary angioedema in Sweden. Allergy Asthma Proc 2014,
35:185–190.
26. Weigl JA, Puppe W, Rockahr S, Schmitt HJ: Burden of disease in hospitalized
RSV-positive children in Germany. Klin Padiatr 2002, 214(6):334–342.
27. Tabolli S, Sampogna F, Di Petro C, Paradisi A, Uras C, Zotti P, Castiglia D,
Zambruno G, Abeni D: Quality of life in patients with epidermylosis
bullosa. Br J Dermatol 2009, 161(4):869–877.
28. Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT: The
humanistic burden of hereditary angioedema: Impact on health-related
quality of life, productivity, and depression. Allergy Asthma Proc 2010,
31:407–414.
doi:10.1186/1750-1172-9-99
Cite this article as: Aygören-Pürsün et al.: Socioeconomic burden of
hereditary angioedema: results from the hereditary angioedema burden
of illness study in Europe. Orphanet Journal of Rare Diseases 2014 9:99.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
